Publications by authors named "Udo zur Stadt"

Claim this Profile
C
Characterization of a PRKCE::ETV6 fusion as a potential oncogenic driver in T-cell acute lymphoblastic leukemia.
Esther L Monsees, Udo Zur Stadt, Julia Strauss, Sabrina Schuster, Nadja Kleist

Mol Cell Pediatr· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal t(2;5) translocation - implementation for the selection of MRD-targets.
Esther L Monsees, Richard T Hauch, Antonina Wrzeszcz, Michael Spohn, Julia Strauss, Udo Zur Stadt

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB::NOTCH1 fusions with unfavorable outcome.
Marcel Te Vrugt, Janna Wessolowski, Gerrit Randau, Amelie Alfert, Stephanie Mueller, Udo Zur Stadt

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
Jette Luedersen, Udo Zur Stadt, Julia Richter, Ilske Oschlies, Wolfram Klapper

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia.
Inge van Outersterp, Vincent H J van der Velden, Patricia G Hoogeveen, Goda E Vaitkevičienė, Edwin Sonneveld, Udo Zur Stadt

Hemasphere· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Kerstin Mezger, Sabine Ebert, Hannah Elisa Muhle, Udo Zur Stadt, Arndt Borkhardt

Pediatr Blood Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.
Paula Möker, Udo Zur Stadt, Martin Zimmermann, Malik Alawi, Stephanie Mueller

Leukemia· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Gabriele Escherich, Udo Zur Stadt, Arndt Borkhardt, Dagmar Dilloo, Jörg Faber

Haematologica· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Naomi Michels, Judith M Boer, Amir Enshaei, Rosemary Sutton, Mats Heyman, Udo Zur Stadt

Lancet Haematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional flow cytometry of monocytes for routine diagnosis of innate primary immunodeficiencies.
Sandra Ammann, Sebastian Fuchs, Lydia Martin-Martin, Carla N Castro, Benedikt Spielberger, Udo Zur Stadt

J Allergy Clin Immunol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ulceration in Prolidase Deficiency: Successful Treatment with Anticoagulants.
Kira Süßmuth, Dieter Metze, Ana-Maria Muresan, Kai Lehmberg, Udo Zur Stadt

Acta Derm Venereol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
Franziska Schramm, Udo Zur Stadt, Martin Zimmermann, Norbert Jorch, Arnulf Pekrun

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
Udo Zur Stadt, Malik Alawi, Manuela Adao, Daniela Indenbirken, Gabriele Escherich

Blood Cancer J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
Jessica I Hoell, Sebastian Ginzel, Michaela Kuhlen, Andreas Kloetgen, Michael Gombert, Udo Zur Stadt

Blood Adv· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.
Jana Hoffmann, Manuela Krumbholz, Helia Pimentel Gutiérrez, Marion Fillies, Annabell Szymansky, Udo Zur Stadt

Pediatr Blood Cancer· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia.
Bruno A Lopes, Claus Meyer, Thayana C Barbosa, Caroline P Poubel, Marcela B Mansur, Udo Zur Stadt

Transl Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is an infectious trigger always required for primary hemophagocytic lymphohistiocytosis? Lessons from in utero and neonatal disease.
Maximilian Heeg, Sandra Ammann, Christian Klemann, Marcus Panning, Valeria Falcone, Udo Zur Stadt

Pediatr Blood Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, Silja Röttgers, Jeremy Hancock, Udo Zur Stadt

Haematologica· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemophagocytic lymphohistiocytosis as presenting manifestation of profound combined immunodeficiency due to an ORAI1 mutation.
Christian Klemann, Sandra Ammann, Miriam Heizmann, Sebastian Fuchs, Sebastian F Bode, Udo Zur Stadt

J Allergy Clin Immunol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Annabelle Zoghbi, Udo Zur Stadt, Beate Winkler, Ingo Müller, Gabriele Escherich

Pediatr Blood Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of constitutive activation of FMS-related tyrosine kinase-3 and mutational status in infants with -rearranged acute lymphoblastic leukemia.
Henning Fedders, Ameera Alsadeq, Juliane Schmäh, Fotini Vogiatzi, Martin Zimmermann, Udo Zur Stadt

Haematologica· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Immunological Guidance of Genetic Analyses Including Exome Sequencing in Patients Evaluated for Hemophagocytic Lymphohistiocytosis.
Sandra Ammann, Kai Lehmberg, Udo Zur Stadt, Christian Klemann, Sebastian F N Bode

J Clin Immunol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire.
Sandra Ammann, Kai Lehmberg, Udo Zur Stadt, Gritta Janka, Anne Rensing-Ehl

Eur J Immunol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.
Bruno Almeida Lopes, Claus Meyer, Thayana Conceição Barbosa, Udo Zur Stadt, Martin Horstmann

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL.
Udo Zur Stadt, Gabriele Escherich, Daniela Indenbirken, Malik Alawi, Manuela Adao

Pediatr Blood Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis